Header Logo

Connection

DAVID FOGELMAN to Dasatinib

Back to Details
This is a "connection" page, showing publications DAVID FOGELMAN has written about Dasatinib.
DAVID FOGELMAN
Connection Strength
0.114
Dasatinib
  1. Dual Inhibition of EGFR and c-Src by Cetuximab and Dasatinib Combined with FOLFOX Chemotherapy in Patients with Metastatic Colorectal Cancer. Clin Cancer Res. 2017 Aug 01; 23(15):4146-4154.
    View in: PubMed
    Score: 0.114
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.